Abstract

The objective is to estimate the national economic costs associated with undiagnosed diabetes mellitus (UDM). UDM is defined as unknowingly having an elevated glucose level that meets the definition of diabetes. National Health and Nutrition Examination Survey (NHANES) data are used to estimate the prevalence of UDM. Because UDM cannot be directly observed in medical claims for analyzing per capita patterns of health care use, we analyze annual medical claims from a proxy population—people within 2 years of first diagnosis of diabetes. For a commercially insured population first diagnosed with diabetes in 2006 (n = 29,770), we compare their annual health care use in 2004 and 2005 to that of patients with no history of diabetes between 2004 and 2006 (n = 3.2 million). We combine estimates of UDM prevalence from NHANES with health care use patterns from the proxy population to estimate etiological fractions that reflect the portion of national health care use associated with UDM. Approximately 6.3 million adults in the United States have UDM in 2007. Annual per capita use of health care services for the UDM proxy population is higher than for a comparable group with no history of diabetes, but lower than for a comparable group with a history of diabetes. The estimated economic costs of UDM in 2007 is $18 billion ($2864 per person with UDM), including medical costs of $11 billion and indirect costs of $7 billion. Although the high prevalence of UDM makes it an important health issue to be studied, data limitations have contributed to a dearth of information on the health care use patterns and economic costs of UDM. By omitting UDM, estimates of the total national cost of diabetes are underestimated. (Population Health Management 2009;12:95–101)

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Population Health Management
Population Health Management
Volume 12Issue Number 2April 2009
Pages: 95 - 101
PubMed: 19361252

History

Published online: 10 April 2009
Published in print: April 2009

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Yiduo Zhang
The Lewin Group, Falls Church, Virginia.
Timothy M. Dall
The Lewin Group, Falls Church, Virginia.
Sarah E. Mann
The Lewin Group, Falls Church, Virginia.
Yaozhu Chen
The Lewin Group, Falls Church, Virginia.
Jaana Martin
The Lewin Group, Falls Church, Virginia.
Victoria Moore
Ingenix/i3 Pharmainformatics, Cary, North Carolina.
Alan Baldwin
Ingenix/i3 Pharmainformatics, Cary, North Carolina.
Viviana A. Reidel
Ingenix/i3 Research, Basking Ridge, New Jersey.
William W. Quick
Ingenix/i3 Research, Basking Ridge, New Jersey.

Notes

Address reprint requests to:
Yiduo Zhang, Ph.D.
The Lewin Group, Falls Church
3130 Fairview Park Drive, Suite 800
Falls Church VA 22042
E-mail: [email protected]

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top